Mircera belongs to a class of drugs known as erythropoiesis stimulating agents, or ESAs, that have been the subject of a safety review by the FDA.

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically ...

The judge refereeing the turf battle between Roche and Amgen over anemia meds has taken a time-out to consult the experts. Judge William Young said he's grappling "with complex issues" in the patent ...

Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring U.S. sales of the anemia med, claiming that Mircera doesn't infringe on Amgen's ...

(CN) – The Federal Circuit refused to lift an injunction barring F. Hoffman-La Roche Ltd. from importing its anemia treatment, Mircera, to the United States, saying the drug infringes on some of Amgen ...

Mircera is an erythropoietin receptor activator with greater activity in vivo as well as increased half-life, in contrast to erythropoietin. It is formulated as a sterile, preservative-free ...

FDA delay on Mircera a reprieve for Amgen, J&J . The FDA delayed an approval decision on Roche’s Mircera pending a fall advisory committee review, spelling temporary relief for marketers of similar ...

LONDON (MarketWatch) -- Swiss drugmaker Roche said Friday that it has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending a marketing ...

Amgen Inc. has won a key patent trial that it hopes will prevent Roche Holding AG from launching its anemia drug Mircera in the U.S. The victory Tuesday will likely protect Amgen's most valuable ...

Amgen Inc. said a federal court granted the biotechnology company a permanent injunction prohibiting Roche Holding AG from selling its Mircera anemia treatment in the U.S., while also upholding a ...